Cytokinetics Inc
(STU:KK3A)
€
46.8
-0.8 (-1.68%)
Market Cap: 5.58 Bil
Enterprise Value: 5.34 Bil
PE Ratio: 0
PB Ratio: 56.37
GF Score: 56/100 Cytokinetics Inc at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019 / 12:10PM GMT
Release Date Price:
€12.05
(-5.93%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
For this first session, we have Robert Blum, President and CEO of Cytokinetics. Welcome.
Robert I. Blum
Cytokinetics, Incorporated - CEO, President & Director
Thank you, Jeff.
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
Maybe for those in the room who may not be familiar with Cytokinetics, can you provide a brief introduction?
Robert I. Blum
Cytokinetics, Incorporated - CEO, President & Director
Sure. So firstly, thank you for inviting us to participate in the conference. Cytokinetics is a company that is focused to muscle biology, and we've pioneered the biology of this space over the course of 20 years. I started the company in 1998 with leading scientists in the field who were luminaries in this space pertaining to the biochemistry and the biophysics of protein interactions that give rise to muscle force and power and muscle endurance or stamina.
And over the course of
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot